3.24
다형성은 다형체라고 알려진 여러 결정 형태로 약물 물질이 존재하는 것을 말합니다. 최근에 이 용어는 용매화물(용매를 포함하는 형태), 비정질 형태(비결정 형태), 탈용매화 용매화물(용매가 제거된 형태)을 포함하도록 확장되었습니다.
일부 다형성 결정은 비정질 결정보다 수…
약물 용해는 다형성(polymorphism)의 영향을 받는데, 이는 다형체(polymorphs), 용매화물(solvates) 및 비정질 형태(amorphous form)와 같은 여러 결정 형태의 약물 물질이 존재하는 것을 말합니다.
약물의 다형체는 동일한 화학식을 공유하지만 화학 구조가 다르기 때문에 물리적 특성이 다릅니다.
예를 들어, 클로람페니콜 현탁액에는 여러 결정 형태가 있습니다. 그러나 수용성이 높은 β-다형체의 비율이 높을수록 약물 흡수가 향상됩니다.
준안정 다형체는 제조 중에 보다 안정적인 형태로 변환될 수 있으며 정제 균열 또는 과립화 압축 방지와 같은 문제를 일으킬 수 있습니다.
제조 과정에서 일부 약물은 용매와 상호 작용하여 용매를 형성합니다. 이러한 용매 화합물의 다양한 결정 형태를 pseudopolymorphs라고합니다.
용매가 물이면 수화물이 형성됩니다. 에리트로마이신 수화물의 경우, 시간 대비 용존 비율의 플롯은 이수화물, 일수화물 및 무수화물 형태에 대해 서로 다른 용해도 패턴을 보여줍니다.
마지막으로, 비정질 형태는 결정 구조가 없으며 결정보다 수용액에서 더 빨리 용해됩니다.
View the full transcript and gain access to JoVE Core videos
Q1: What is polymorphism and how does it affect drug dissolution?
Polymorphism refers to a drug substance existing in multiple crystalline forms with the same chemical formula but different structures and physical properties. Different polymorphs exhibit varying solubility rates; for example, chloramphenicol's highly soluble β-polymorph enhances drug absorption compared to less soluble forms. This variation directly impacts dissolution rates and bioavailability.
Q2: Why do metastable polymorphs cause problems during drug manufacturing?
Metastable polymorphs can convert to more stable forms during manufacturing, causing tablet cracking or preventing granulation compression. These transitions occur because metastable forms possess higher free energy than stable polymorphs. Such changes may require product reformulation to maintain pharmaceutical quality and efficacy.
Q3: What are solvates and pseudopolymorphs in pharmaceutical formulations?
Solvates form when drugs interact with solvents during manufacturing. When water is the solvent, specific crystalline forms called hydrates are produced. These pseudopolymorphs possess different solubility characteristics than their anhydrous counterparts; for instance, erythromycin hydrates show distinct dissolution patterns compared to the anhydrate form.
Q4: How do amorphous drug forms compare to crystalline forms in dissolution?
Amorphous forms lack crystalline structures and dissolve more rapidly in aqueous solutions than crystalline forms. Being less structurally rigid, amorphous drugs often exhibit faster dissolution rates. However, some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, potentially leading to incomplete absorption.
Q5: Why does anhydrous ampicillin absorb faster than ampicillin trihydrate?
The anhydrous form of ampicillin dissolves more quickly than ampicillin trihydrate, resulting in faster absorption. This difference stems from the distinct solubility characteristics of hydrated versus anhydrous forms. Faster dissolution of the anhydrous form enables more rapid drug availability for mechanisms of drug absorption paracellular transcellular and vesicular transport.
Q6: What determines whether a polymorph is stable or metastable?
The most stable polymorph has the lowest free energy, making it thermodynamically favored. Metastable polymorphs possess higher free energy and may spontaneously transition to more stable forms over time. This energy difference explains why certain crystal forms persist during manufacturing while others convert, potentially causing formulation problems.
Q7: How do hydrate forms of erythromycin differ in their dissolution behavior?
Erythromycin exists in dihydrate, monohydrate, and anhydrate forms, each displaying different solubility patterns. When percent dissolved is plotted against time, these hydrate forms show distinct dissolution curves. The variation in water content directly influences the crystal structure and aqueous solubility of each form.